Abstract 335P
Background
Neoadjuvant chemotherapy (NAC) of newly diagnosed breast cancer is used to improve resectability, reduce the extent of breast and axillary surgery and improve overall survival. Accurate assessment of locoregional response to NAC is important for surgical planning. Radiological method of choice is post-treatment breast magnetic resonance imaging (MRI), which determines the rate of response according to RECIST criteria. The primary indicator of outcome of NAC is pathologic complete response (pCR). This study aimed to compare radiologic and pathologic complete response rates after neoadjuvant treatment of early breast cancer.
Methods
A retrospective study of 259 breast cancer cases who received NAC between 01.01.2020 and 31.12.2021 at University Hospital Centre Zagreb was conducted with prior Ethics Committee approval. Radiological and pathohistological characteristics of the tumor at the time of diagnosis and after neoadjuvant treatment were analyzed using the Hospital information system (BIS). Furthermore, post-neoadjuvant therapy MRI findings were correlated with the postoperative pathohistological findings. Sensitivity, specificity, accuracy, and positive predictive value of radiologic complete response (rCR) as a predictor of pCR were calculated.
Results
Complete data was available for 94.98% (246/259) of patients. In 62 (25.20%) patients, rCR was recorded, radiologic partial response (rPR) in 150 (60.98%), stable disease in 22 (8.94%), and progressive disease in 9 patients. In 78 (31.71%) patients pCR was achieved, 46 (58.97%) were also classified as rCR, while 32 (41.03%) of those showed a radiological stable disease or rPR. Out of the 62 patients with rCR, 16 (25.81%) did not achieve pCR. The sensitivity and specificity of rCR were 90.48% and 58.97%, respectively, while positive predictive value was 82.61%. The overall accuracy of breast MRI in predicting pCR was 80.49%.
Conclusions
Although the sensitivity of breast MRI in predicting pCR was high, the specificity was low with only moderate overall accuracy. Low specificity can lead to an incorrect choice of breast surgery, therefore a better method of evaluation is necessary.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Krizic, N. Dedic Plavetic, T. Silovski: Financial Interests, Personal, Research Funding: Roche. All other authors have declared no conflicts of interest.
Resources from the same session
282P - Analysis of Prosigna in hormone receptor-positive early-stage breast cancer cohort after 8 years of experience at a single institution
Presenter: DANIEL MORCHÓN ARAUJO
Session: Poster session 02
283P - Patient profiles treated with extended adjuvant neratinib in the early access registry study: NEAR study
Presenter: Michelino De Laurentiis
Session: Poster session 02
284P - Prognostic and predictive impact of uPA/PAI-1 in early breast cancer
Presenter: Vanessa Wieder
Session: Poster session 02
285P - Treatment patterns and clinical outcomes of germline BRCA mutation (gBRCAm)-associated breast cancer (BC): A matched, case-control study
Presenter: Stefania Morganti
Session: Poster session 02
286P - Prognostic role of HER2 expression in patients with ER-positive/HER2-negative breast cancer: Results from a population-based cancer registry study
Presenter: Antonino Musolino
Session: Poster session 02
287P - Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer
Presenter: Johan Staaf
Session: Poster session 02
288P - Prognostic factors in nonmetastatic HER2 ‘low’ & HER2 ‘negative’ breast cancer: Single institute experience
Presenter: Alper Türkel
Session: Poster session 02
289P - Results of the window-of-opportunity clinical trial D-BIOMARK: Study of biomarkers of the antitumor activity of denosumab and its role as a modulator of the immune response in early breast cancer
Presenter: Andrea Vethencourt
Session: Poster session 02
290P - Metabolomic profiling and response to neoadjuvant therapy (NAT) in early breast cancer (EBC)
Presenter: Alessandra Gennari
Session: Poster session 02
291P - Prognostic implications of HER2 gain in patients with HR+/HER2- breast cancer (BC) and TNBC after neoadjuvant chemotherapy (NAC)
Presenter: Emanuela Ferraro
Session: Poster session 02